Page 32 - David Clair News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article MINNEAPOLIS, Jan. 28, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced an initial minority strategic equity investment in Changzhou Eminence Biotechnology Co., Ltd. ("Eminence").  Eminence will use the financing proceeds to expand its manufacturing capacity and increase the service capabilities of its China-headquartered GMP media production facility.  Eminence will benefit from Bio-Techne's in...

/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 2, 2021, at...

ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing ScaleReady, a joint venture between Bio-Techne (NASDAQ: TECH), Fresenius Kabi, and Wilson Wolf, launches today. The new company brings together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing from its founding partners. ScaleReady provides leading therapeutic developers with the most simple, scalable, and versatile manufacturing platform in the industry, enhancing the prospect...

ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf ScaleReady's mission is to make the business of cell and gene therapy practical and viable by providing the most simple, scalable and versatile manufacturing platform in the industry ScaleReady will provide sales, marketing, and application support for customers globally ScaleReady, a joint venture between Bio-Techne (NASDAQ: TECH), Fresenius Kabi, and Wilson Wolf, launches today. The new company brings together proven tools and ...